Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses

Trillitye Paullin¹, Chase Powell¹, Christopher Menzie¹, Robert Hill¹, Feng Cheng²,³, Christopher J. Martyniuk¹*, Sandy D. Westerheide¹*

¹ Department of Cell Biology, Microbiology, and Molecular Biology, College of Arts and Sciences, University of South Florida, Tampa, Florida, United States of America, ² Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, Florida, United States of America, ³ Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, Florida, United States of America, ⁴ Center for Environmental and Human Toxicology & Department of Physiological Sciences, UF Genetics Institute, University of Florida, Gainesville, Florida, United States of America

* cmartyn@ufl.edu (CJM); swesterheide@usf.edu (SDW)

Abstract

Ovarian cancer is the most lethal gynecological cancer, with over 200,000 women diagnosed each year and over half of those cases leading to death. These poor statistics are related to a lack of early symptoms and inadequate screening techniques. This results in the cancer going undetected until later stages when the tumor has metastasized through a process that requires the epithelial to mesenchymal transition (EMT). In lieu of traditional monolayer cell culture, EMT and cancer progression in general is best characterized through the use of 3D spheroid models. In this study, we examine gene expression changes through microarray analysis in spheroid versus monolayer ovarian cancer cells treated with TGFβ to induce EMT. Transcripts that included Coiled-Coil Domain Containing 80 (CCDC80), Solute Carrier Family 6 (Neutral Amino Acid Transporter), Member 15 (SLC6A15), Semaphorin 3E (SEMA3E) and PIF1 5'-To-3' DNA Helicase (PIF1) were downregulated more than 10-fold in the 3D cells while Inhibitor Of DNA Binding 2, HLH Protein (ID2), Regulator Of Cell Cycle (RGCC), Pro tease, Serine 35 (PRSS35), and Aldo-Keto Reductase Family 1, Member C1 (AKR1C1) were increased more than 50-fold. Interestingly, EMT factors, stress responses and epigenetic processes were significantly affected by 3D growth. The heat shock response and the oxidative stress response were also identified as transcriptome responses that showed significant changes upon 3D growth. Subnetwork enrichment analysis revealed that DNA integrity (e.g. DNA damage, genetic instability, nucleotide excision repair, and the DNA damage checkpoint pathway) were altered in the 3D spheroid model. In addition, two epigenetic processes, DNA methylation and histone acetylation, were increased with 3D growth. These findings support the hypothesis that three dimensional ovarian cell culturing is physiologically different from its monolayer counterpart.
Introduction

Despite recent improvements in surgery and chemotherapy, ovarian cancer is still the leading cause of death from gynecological malignancy [1]. Due to poor detection methods and a lack of symptoms, most patients are diagnosed at advanced stages, when the tumor has metastasized and spread [2]. Studies suggest that in order for metastasis to occur, the cancer cells must undergo phenotypic changes modulated by the epithelial-mesenchymal transition (EMT) [3].

EMT is a distinct process whereby epithelial cells undergo changes in favor of mesenchymal properties [4]. This process is most commonly observed during developmental stages when epithelial cells must migrate and dedifferentiate, such as in the formation of the mesoderm during gastrulation [5]. In order to properly study this phenomenon, scientists have discovered multiple factors and signals which can induce EMT. Of these, the most popular inducer is transforming growth factor β (TGFβ) [6, 7]. The addition of TGFβ to epithelial cells induces transient EMT within hours of treatment through activation of the Smad pathway [8].

Although two dimensional (monolayer) tissue culture models are largely used to study the EMT process, evidence suggests that three dimensional (spheroid) culturing may be more physiologically relevant as it better emulates oxygen levels, pH conditions, glucose levels, extracellular matrix strength, and overall morphology of in vivo solid tumors [9–12]. This is especially the case when focusing on metastasis, tissue invasion, angiogenesis, and drug sensitivity [13–15].

At least a third of ovarian cancer patients present with ascites [16]. Ascites is the accumulation of fluid in the peritoneal cavity which may contain ovarian cancer cells, lymphocytes, and mesothelial cells in the form of single cells and aggregates [17]. Further studies revealed that ascites spheroids may cause secondary tumors due to their ability to adhere to extracellular matrix proteins via interaction between multiple integrins and their ligands [18, 19]. Here, we conducted a comprehensive gene expression analysis for the process of culturing HEY epithelial ovarian cancer cells in 3D vs. 2D cultures during the TGFβ-induced EMT process. Using subnetwork enrichment analysis, we identified stress pathways, DNA integrity pathways, and epigenetic processes as those most affected by 3D vs. 2D growth.

Materials and methods

Cells culture and treatments

The HEY human ovarian cancer cell line (kindly provided by Dr. Meera Nanjundan, University of South Florida, Tampa, FL) was authenticated by short tandem repeat (STR) DNA profiling (Genetica, Inc.) and was compared to ATCC and previously published profiles [20]. Cells were cultured in a humidified incubator containing 5% CO₂ at 37°C in RPMI with 10% fetal bovine serum and 1% Pen-Strep-Glutamine. Spheroid formation was accomplished through the hanging drop method. Briefly, trypsinized HEY cells were resuspended at 1 ⋅ 10⁶ cells/mL in supplemented RPMI. Multiple 25 µl droplets of the cell solution were then placed onto plate lids, inverted, and incubated for 72 hours to allow cells to aggregate into spheroids. To induce EMT, a final concentration of 10 ng/µl TGFβ was added to cells and incubated for 72 hours as monolayer cell culture or hanging drops during the creation of spheroids. Following incubation, monolayer cells and spheroids were photographed using an Evos® FL Cell Imaging microscope (ThermoFisher Scientific) and then collected in 1X PBS.

Quantitative RT-PCR

RNA was extracted from harvested cells using the RNeasy Mini Kit (Qiagen). RNA samples were then reversed transcribed with a High Capacity cDNA Reverse Transcription Kit.
(Applied Biosystems) per the manufacturer’s instructions. Subsequent samples were then diluted to 50 ng/μL and used as a template for quantitative PCR (qPCR). qPCR was accomplished with a Step One Plus Real-time PCR system (Applied Biosystems) and SYBR® Green Supermix with ROX (BioRad) according to the manufacturer’s protocol. Relative mRNA levels were quantified for \textit{ahnak2}, \textit{akr1c1}, \textit{ccdc80}, \textit{hspa1a}, \textit{hsph1}, \textit{prss35}, \textit{rgs2}, and \textit{rrad} using gene-specific primers (S1 Table).

**Affymetrix GeneAtlas Platform and 3'IVT compatible U219 probe arrays**

The oligonucleotide probe arrays used were the Affymetrix HG-U219 human array strips. These arrays consist of more than 530,000 probes detecting over 36,000 transcripts and variants-representing more than 20,000 genes.

**Sample processing and validation**

HEY Human ovarian carcinoma cells treated with TGFβ were cultured as 2-dimensional monolayers or as 3-dimensional spheroids using the hanging drop method. Replicates of 4 separate experiments were performed on 4 different culturing days. Cells were then harvested and total RNA was isolated from all 8 samples using Qiagen’s RNeasy Mini Kit according to the manufacturer’s instructions. RNA integrity was verified with 1 μl of total RNA on RNA 6000 nanochips (Agilent) using The Agilent 2100 Bioanalyzer. All results for all 8 samples reported RNA Integrity Numbers (RIN) > 9. 100 ng of polyadenylated RNA was converted to cDNA and then amplified and labeled with biotin using Affymetrix 3'IVT Expression System according to the manufacturer’s instructions. Hybridization with the biotin-labeled RNA, staining, and scanning of the chips followed the procedure outlined in the Affymetrix technical manual. You can put this at the end of the methods on the micro array hybridization. All microarray data have been deposited into Gene Expression Omnibus (GSE80373).

**Data analysis**

Scanned output files were visually inspected for hybridization artifacts and then annotated and normalized using Affymetrix Expression Console v1.3.1. Additionally, all QC metrics reported no outlier samples. Signal intensity was scaled to an average intensity of 500 during comparison analysis. Annotated expression data were assigned an ANOVA P value for the likelihood that any perceived difference was due to chance. The P values for all probe sets were exported to a text file and all pairwise comparisons of Bi-weight average signals were then aligned in MS Excel. For the comprehensive analysis, \( P < 0.05 \) was identified as having a linear change (increased or decreased) for the comparison. This analysis reported ~3,329 genes that showed differential regulation greater or less than 2-fold. To increase stringency, only genes whose fold-change was greater than or less than four (\( p < 0.05 \)) were considered to be differentially expressed, reducing the pool to 493 candidate genes.

Data were analyzed using different visualization techniques that included hierarchical clustering, principle component analysis (PCA), and volcano plots. All analyses were conducted in JMP Genomics v7.0. Transcripts that showed \( p < 0.01 \) were used in the two-way clustering using the Fast ward algorithm after each row was centered to a mean of zero (0) and variance scaled to one. Results from hierarchical cluster analyses were visualized using heat map dendrograms, and biological replicates were partitioned into groups based on similarity (i.e., individuals clustered together are most similar). PCA used spatially weighted averages and were conducted on normalized expression values, the same dataset used in the cluster analysis. Volcano plots were generated in JMP Genomics 7.0 following an ANOVA to identify differentially expressed transcripts.
Pathway Studio analysis

Pathway Studio 9.0 (Elsevier) and ResNet 10.0 were used for sub-network enrichment analysis (SNEA) of cell processes [21]. The option of “best p value, highest magnitude fold change” in Pathway Studio was used for duplicated probes. Transcripts were successfully mapped using GeneBank ID. SNEA was performed to identify gene networks that were significantly different. A Kolmogorov–Smirnov test with 1000 permutations was conducted to determine whether certain networks were preferentially regulated compared to the background reference probability distribution. Networks were constructed based on common regulators of expression and regulators of specific cell processes. The enrichment P-value for a gene seed was set at $P < 0.05$. Additional details on the use of SNEA can be found in Langlois and Martyniuk [22].

Results and discussion

HEY cells treated with TGFβ have distinct gene expression profiles when grown as 3D spheroids vs. 2D monolayers

To examine whether growth of HEY ovarian cancer cells as 3D spheroids vs. 2D monolayers could influence gene expression, we performed microarray analysis on four biological replicates of cells grown under each condition. To create spheroids, the hanging drop method [23] was used as outlined (Fig 1). We find that HEY cells treated with TGFβ have distinct gene expression profiles, depending on whether they are cultured under 2D vs. 3D conditions (Fig 2). Hierarchical clustering reveals that each of the two groups form into distinct clades based on gene expression (Fig 2A). Additionally, principle component analysis shows that biological quadruplicates for HEY 2D and HEY 3D samples are more similar to themselves than to each other.
Fig 2. HEY cells treated with TGFβ have distinct gene expression profiles when grown as 3D spheroids vs. 2D monolayers. A) Hierarchical clustering of expression profiles. Clustering revealed that each of the two groups (4 biological replicates per group) form into distinct clades based on expression. B) Principle component analysis for expression profiles.
Variability in transcriptome response separates strongly along the first PCA1. Red color is HEY 3D biological replicates and green color is HEY 2D biological replicates. The four biological replicates for HEY 2D are more closely related in expression as compared to HEY 3D.

RT-qPCR was performed on eight different genes which were found to be up or downregulated by varying degrees upon 3D culturing to validate our microarray analysis (Fig 3). The

![Real Time PCR and Microarray graphs](https://doi.org/10.1371/journal.pone.0182930.g003)

**Fig 3. Real time PCR analysis validates microarray results.** A) Real time PCR results for select genes that are moderately to highly affected by 3D vs. 2D growth. B) Microarray results are plotted for the same genes.
eight genes we chose to validate include two highly upregulated genes, the serine protease PRSS35 and the aldo-keto reductase AKR1C1, as well as the highly downregulated E-cadherin regulator CCDC80. Additionally, we chose some genes that were more moderately regulated, including the chaperones HSP110 and HSP70, the G-protein signaling inhibitor RGS2, the fibroblast growth factor secretion regulator AHNAK2 and the apoptotic inducer RRAD. Our results show that similar trends are observed via RT-qPCR for these genes as compared to our microarray results. Overall, our data show that HEY ovarian cancer cells, treated with TGFβ to induce EMT, show dramatic differences in gene expression profiles when grown as 3D spheroids vs. standard 2D culture.

Transcripts affected by 3D culturing may enhance the tumorigenicity of HEY cells

Growth as 3D spheroids leads to both the upregulation and downregulation of gene expression (Table 1. For a complete list of gene expression data see S2 Table). The most highly upregulated gene under 3D growth conditions in HEY cells is AKR1C1 (Aldo-Keto Reductase Family 1, Member C1), part of a family of cytosolic NADP(H)-dependent oxidoreductases that is involved in detoxification of xenobiotics, steroids, and polycyclic aromatic hydrocarbons [24]. Increased expression of AKR1C1 is associated with the development of cisplatin resistance in human ovarian carcinoma cells [25]. Previous work shows that ovarian cancer cells, grown in 3D, are more resistant to chemotherapy treatment [26]. It is therefore plausible that the increased expression of AKR1C1 upon ovarian cancer cell 3D growth may promote chemotherapy resistance. PRSS35 (Protease, Serine 35), another highly upregulated gene upon 3D growth, belongs to the trypsin class of serine proteases. This protease is highly expressed in the mouse ovary [27]. Proteases play an important role in proteolysis that is essential for tissue remodeling that occurs during EMT by breaking down the extracellular matrix. While metalloproteases play the largest role in this process, serine proteases also contribute [28]. We postulate that enhanced expression of PRSS35 under 3D growth conditions may promote ovarian EMT through the proteolytic digestion of cell attachments. A transcript that was highly downregulated upon 3D growth is CCDC80 (Coiled-Coil Domain Containing 80). Interestingly, CCDC80 null mice develop thyroid adenomas and ovarian carcinomas, and CCDC80 gene expression is decreased in human ovarian cancer samples as compared to normal ovarian samples [29]. The mechanism for the tumor suppressor properties of CCDC80 may be through its ability to induce E-cadherin expression [29]. E-cadherin provides crucial cell-cell adhesion to hold epithelial cells tightly together, and enhanced E-cadherin expression promotes the epithelial phenotype over the cancer-promoting mesenchymal phenotype [30]. Collectively, we propose that regulation of these and other genes upon 3D growth may enhance the tumorigenic properties of ovarian cancer cells.

Gene-set enrichment analysis reveals novel pathways that are enriched upon HEY cell growth as 3D spheroids

Gene set enrichment analysis suggested that pathways downregulated by more than 15% include branched chain amino acid metabolism, folate biosynthesis, fatty acid oxidation, and the mevalonate pathway, while pathways upregulated in the 3D cells include those related to tumor necrosis factor receptor (TNFR) superfamily member 1A and 6 (for a complete list of gene set enrichment pathways identified see S3 Table). These pathways were increased more than 20% with 3D growth in HEY cells, and they have all been related to cancer growth. Branched chain amino acids, such as leucine, positively regulate the mammalian-target-of-rapamycin (mTOR) pathway [31]. The mTOR pathway is involved in regulating cellular
functions involved in growth and proliferation, and upregulation of this pathway is commonly observed in human cancers [32]. Folate plays a role in nucleotide synthesis and methylation, making it essential to rapidly growing cancer cells [33]. Fatty acid oxidation is required for

### Table 1. The most differentially expressed transcripts in the HEY 3D compared to HEY 2D.

| Direction of Change | Gene   | Role                                                                 | Fold Change | p-value   |
|---------------------|--------|----------------------------------------------------------------------|-------------|-----------|
| Down-regulated      | CCDC80 | Heparin binding and fibronectin binding                              | -17.39      | 2.87E-09  |
|                     | SLC6A15| Amino acids transport                                                | -14.75      | 2.3E-08   |
|                     | SEMA3E | Axon guidance ligands                                                | -14.67      | 9.33E-09  |
|                     | TENM2  | Protein homodimerization activity                                     | -13.13      | 2.43E-08  |
|                     | PLCB4  | Catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol | -13.09      | 2.91E-08  |
|                     | MIR17  | Involved in cancer and cell carcinomas                               | -13.09      | 1.09E-08  |
|                     | PIF1   | 5' to 3' DNA helicase                                                 | -11.49      | 1.16E-08  |
|                     | IL1RAP | Associates with interleukin to mediate NF-κB signaling                | -10.83      | 6.66E-09  |
|                     | GPR126 | G-protein orphan receptor                                             | -9.92       | 5.7E-10   |
|                     | PLCB4  | Catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol | -9.29       | 7.77E-09  |
|                     | DLEU2  | Associated with chronic lymphocytic leukemia                          | -9.09       | 4.32E-09  |
|                     | TIGD1  | Unknown                                                               | -8.99       | 6.51E-08  |
|                     | TPM1   | Involved in the contractile system of striated and smooth muscles     | -8.91       | 9.32E-08  |
|                     | KRTAP2 | Formation of a rigid and resistant hair shaft                         | -8.78       | 4.61E-09  |
|                     | RIMS2  | Ion channel binding and Rab GTPase binding                           | -8.77       | 6.8E-10   |
|                     | ATP8B1 | Transport of phosphatidylserine and phosphatidylethanolamine          | -8.60       | 7.27E-10  |
|                     | AHNAK2 | Cell differentiation                                                  | -8.56       | 8.9E-09   |
|                     | AKAP12 | Scaffold protein in signal transduction                              | -8.08       | 5.87E-09  |
| Up-regulated        | MRPS6  | Protein synthesis in mitochondria                                     | 18.96       | 5.7E-10   |
|                     | TNFSF15| Cytokine inducible by TNF and IL-1α                                   | 20.18       | 2.85E-08  |
|                     | RANBP3L| Binding protein                                                       | 20.29       | 3.27E-09  |
|                     | SLC1A3 | Termination of excitatory neurotransmission in central nervous system | 22.47       | 1.07E-09  |
|                     | TMEM171| Unknown                                                               | 24.17       | 7.76E-10  |
|                     | AKR1B1 | Catalyzes the reduction of aldehydes                                  | 24.76       | 4.53E-10  |
|                     | F2RL1  | Receptor for trypsin and trypsin-like enzymes coupled to G proteins   | 25.68       | 5.85E-10  |
|                     | S100A4 | Cell cycle progression and differentiation                            | 28.15       | 5.7E-10   |
|                     | PTGS2  | Prostaglandin biosynthesis                                            | 29.55       | 3.06E-08  |
|                     | SOD2   | Converts superoxide byproducts to H2O2                                | 32.39       | 4.72E-09  |
|                     | CXCR4  | CXC chemokine receptor                                                | 35.08       | 6.24E-10  |
|                     | IL8    | Neutrophil chemotactic factor                                         | 55.81       | 7.76E-10  |
|                     | SPOCK1 | Protease inhibition                                                   | 56.98       | 6.76E-10  |
|                     | NADK2  | Catalyzes the phosphorylation of NAD to yield NADP                   | 57.98       | 2.16E-08  |
|                     | GLS    | Catalyzes the hydrolysis of glutamine to glutamate                    | 59.61       | 6.06E-08  |
|                     | ITGB8  | Mediate cell-cell and cell-extracellular matrix interactions          | 60.23       | 2.1E-09   |
|                     | ID2    | Cellular growth, senescence, differentiation, apoptosis, angiogenesis | 70.77       | 4.63E-09  |
|                     | RGCC   | Regulates cell cycle, induced by p53                                  | 78.93       | 5.85E-10  |
|                     | PRSS35 | Protease activity                                                     | 179.46      | 5.85E-10  |
|                     | AKR1C1 | Conversion of aldehydes and ketones to their corresponding alcohols  | 198.09      | 5.7E-10   |

Transcripts are organized as those down-regulated and up-regulated between the two groups. The gene, as well as the role of the protein in the cell is provided in addition to the relative fold change and p-value. For a complete list of gene expression changes see S2 Table.

https://doi.org/10.1371/journal.pone.0182930.t001
functional angiogenesis and is utilized by cancer cells to overcome metabolic stress to proliferate [34]. The mevalonate pathway is responsible for converting acetyl-coenzyme A into isoprenoids, which are required for cholesterol and steroid synthesis [35]. LDL-cholesterol accumulates in cancer tissues and is associated with migration, proliferation, and loss of adhesion from the primary tumor which are vital steps in the epithelial to mesenchymal transition [35]. Upregulation of TNFR family members allows signaling via the NF-κB transcription factor, which can promote tumorigenesis through the activation of the expression of genes involved in processes including cell proliferation, migration and anti-apoptosis [36]. Therefore, we conclude that multiple cellular pathways that are altered upon 3D growth could increase tumorigenicity.

EMT genes are altered upon spheroid culturing in ovarian cancer

Unique sub-networks underlie the transition from 2D to 3D growth in HEY cells (Table 2, for a complete list of enriched cell networks see S3 Table). We note that many of the genes involved in EMT are differentially expressed upon formation of spheroids as compared to growth in monolayer (Fig 4). EMT transcription factors downregulate the expression of cell-cell adhesion proteins and upregulate metastatic proteins, leading to cancer progression [37]. Importantly, a number of EMT transcription factors are enhanced upon growth in 3D, including Snail 1 (SNAI1), Snail 2 (SNAI2), ZEB2, TCF3, and SIX1 (S4 Table). Supporting this finding, in recently published work, we show via qPCR that EMT transcription factors, while slightly upregulated upon TGFβ treatment under 2D growth conditions, are upregulated more significantly when grown in 3D [38]. Thus, 3D growth, through enhanced expression of EMT transcription factors, is likely to allow for a stronger induction of EMT by TGFβ.

Transcriptional networks involving stress pathways are altered in HEY cell growth as 3D spheroids

Interestingly, a number of the identified sub-networks are related to the response to stress (Fig 5, for a complete list of gene networks related to stress see S4 Table). The finding that stress responses are activated upon 3D growth is not surprising, given that growth under these conditions is likely to cause nutrient limitation and hypoxia, among other cellular stresses.

Transcripts in the network that are related to the oxidative stress response include peroxiredoxin 2 (PRDX2) (Fold change = +2.2), catalase (CAT) (+1.3), superoxide dismutase 1, soluble (SOD1) (+1.2), and glutathione S-transferase omega 1 (GST01) (-1.3). Transformation may result from the exposure of cells to reactive oxygen species [39]. Additionally, it has been hypothesized that the rise in cancer diagnosis for older individuals may be due to a lifetime of DNA damage by reactive species accumulated endogenously and exogenously [40]. Oxidative stress activates ERK/MEK and PI3K/AKT pathways and impacts signaling proteins important in cancer such as Ras, Raf, p53, PKC, c-Myc, and Nrf2 [41–43]. The changes detected in the oxidative stress pathway upon growth of HEY cells in 3D may thus promote tumorigenic properties of the cells.

Also changed in 3D cells are transcripts that are associated with the heat shock response. Some examples include heat shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1) (+1.16), heat shock 27kDa protein 1 (HSPB1) (+1.20), and heat shock transcription factor 1 (HSF1) (+1.28). Recent studies have suggested that many cancer types utilize activation of heat shock factor 1 (HSF1), the master regulator of the heat shock response, to stabilize oncogenes within the cell [44]. The heat shock response is a highly conserved response to specific environmental stressors such as heat shock, heavy metals, and oxidative stress [45]. HSF1 promotes the transcription of heat shock protein genes, many of which encode
molecular chaperones. Increased chaperone expression provides a cytoprotective response in advanced cancers with acidic, hypoxic, and nutrient-deprived microenvironments [46]. Elevated levels of one or more chaperones are commonly found in both solid cancer tumors and hematological malignancies [47–51]. In fact, overexpression of HSP27, HSP70, or HSP90

| Theme                        | Gene Set Seed                  | Total # of Neighbors | # of Measured Neighbors | Median change | p-value |
|------------------------------|--------------------------------|----------------------|-------------------------|---------------|---------|
| Autophagy                    | autophagy                      | 418                  | 402                     | 1.08          | 5.9E-06 |
|                              | autophagic cell death           | 78                   | 75                      | 1.15          | 0.00076 |
| Cancer and Aging             | senescence                      | 651                  | 596                     | 1.05          | 7.79E-08|
|                              | cell aging                      | 251                  | 225                     | 1.06          | 2.1E-07 |
|                              | oncogenesis                     | 523                  | 486                     | 1.05          | 1.36E-05|
|                              | epithelial to mesenchymal transition | 551               | 522                     | -1.0087       | 1.99E-07|
| Cell Cycle                   | S phase                         | 857                  | 797                     | 1.05          | 4.38E-09|
|                              | interphase                      | 196                  | 192                     | -1.05         | 1.13E-08|
|                              | G1/S transition                 | 611                  | 558                     | 1.07          | 1.73E-06|
|                              | G2 phase                        | 171                  | 164                     | 1.07          | 2.51E-05|
|                              | cell cycle checkpoint           | 161                  | 150                     | 1.06          | 4.1E-05 |
|                              | exit from mitosis               | 62                   | 59                      | 1.06          | 0.000284|
| Chromosome Separation        | spindle assembly                | 507                  | 478                     | -1.06         | 1.14E-11|
|                              | centriole duplication           | 106                  | 103                     | -1.10         | 6.98E-07|
|                              | mitotic spindle assembly        | 59                   | 58                      | -1.18         | 2.98E-05|
|                              | microtubule/kinetochore interaction | 19               | 19                      | -1.54         | 0.000872|
| DNA Damage and Repair        | response to DNA damage          | 460                  | 428                     | 1.07          | 1.32E-12|
|                              | DNA repair                      | 654                  | 609                     | 1.05          | 1.3E-10 |
|                              | genome instability              | 292                  | 272                     | 1.06          | 4.09E-08|
|                              | genetic instability             | 113                  | 111                     | 1.08          | 3.76E-07|
|                              | nucleotide-excision repair      | 120                  | 113                     | 1.09          | 7.58E-06|
|                              | DNA damage checkpoint           | 126                  | 122                     | 1.06          | 6.2E-05 |
| Protein Modification         | protein degradation             | 470                  | 449                     | 1.06          | 7E-08   |
|                              | ubiquitin-dependent protein degradation | 193              | 186                     | 1.16          | 1.23E-05|
|                              | protein ubiquitination          | 89                   | 88                      | 1.15          | 3.27E-05|
|                              | protein sumoylation             | 167                  | 158                     | 1.13          | 4.71E-05|
| Stress                       | response to oxidative stress    | 166                  | 159                     | 1.06          | 3.55E-05|
|                              | heat-shock response             | 65                   | 59                      | 1.14          | 0.000722|
| Transcription                | poly(A)+ mRNA-nucleus export    | 84                   | 77                      | -1.13         | 9.86E-05|
|                              | Polymerase II transcription      | 75                   | 70                      | 1.13          | 0.000393|
| Other                        | adipocyte differentiation       | 394                  | 367                     | 1.06          | 5.11E-06|
|                              | wall integrity                  | 51                   | 51                      | 1.37          | 5.74E-06|
|                              | myoblast differentiation        | 212                  | 196                     | 1.08          | 1.85E-05|
|                              | nucleocytoplasmic transport     | 122                  | 112                     | 1.10          | 2E-05   |
|                              | adherens junction assembly      | 52                   | 50                      | 1.12          | 2.79E-05|
|                              | skin development                | 69                   | 67                      | 1.10          | 0.000175|
|                              | blood vessel barrier            | 28                   | 28                      | 1.26          | 0.000545|
|                              | leiomyocyt e adhesion           | 25                   | 24                      | -1.14         | 0.000756|

Provided are the total number of neighbors within a network, number of neighbors measured on the microarray, the median fold change of the network, and the p-value. All cell processes differentially expressed between cells are provided in S3 Table. Major themes included those related to cell cycle, DNA damage and repair, and stress.

https://doi.org/10.1371/journal.pone.0182930.t002
correlates with poor prognosis and may contribute to drug resistance in some cancer types [52–55]. Activation of the heat shock response in spheroids may promote cell survival, in the face of multiple cellular stresses, through enhanced expression expression of HSF1 target genes, including molecular chaperones. Further analysis of this spheroid model could offer valuable insight into how HSF1 and HSPs could be utilized as targets for chemotherapy in ovarian cancer patients.

Other examples of stress-related genes that show a high magnitude of response in terms of downregulation include the PIF1 5’-to-3′ DNA helicase homolog (S. cerevisiae) (-13.0), epidermal growth factor receptor (-4.6), far upstream element (FUSE) binding protein (-4.4), and cysteine-rich, angiogenic inducer (-4.4). Increasing transcripts in the network included nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (+10.3), FBJ murine osteosarcoma viral oncogene homolog (+14.7), prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (+29.5), and interleukin 8 (+49.8). Many of these aforementioned transcripts have been shown to play critical roles in the progression of cancer. For example, PIF1 is a DNA-dependent adenosine triphosphate (ATP)-metabolizing enzyme that is required for proper replication and repair during cell division. Studies show that this protein inhibits S-phase progression and reduces proliferation rates of RAS.

**Fig 4. Expression of genes related to EMT in 3D vs. 2D growth.** All these genes in the pathway were differentially expressed at \(P<0.001\) in 3D and are related to the process of EMT. Red indicates the gene is up-regulated and blue indicates the gene is down-regulated. All genes for pathways are listed in S4 Table.

https://doi.org/10.1371/journal.pone.0182930.g004
oncogene-transformed fibroblasts [56], and may therefore be a novel drug target for cancer therapy. Here, the downregulation of PIF1 mRNA may lead to increased proliferative activity during the transition from a non-cancerous cell to a cancerous cell. Our network analysis also identifies DNA duplex unwinding (down regulated -1.49) and S-M checkpoint (down-regulated -1.59) as processes significantly down-regulated in 3D spheroids, processes which may be related to changes in PIF1 expression. In terms of ovarian cancer, there are many studies implicating epidermal growth factor receptor (EGFR) as a key regulator of cell differentiation. Specifically, EGF-induced EMT increases phosphorylation of Akt, ERK1/2, and S6 ribosomal protein, which alters ovarian cancer cell proliferation and differentiation [57]. Additionally, elevated EGFR expression in tumor stroma is linked to aggressive epithelial ovarian cancer in patients and relates to Ki-67 expression in tumor cells [58]. In terms of up-regulated transcripts, notable transcripts included FBJ murine osteosarcoma viral oncogene homolog, a member of the Fos family of transcription factors. In cancer, this gene is a proto-oncogene implicated in cell proliferation and transformation [59]. Lastly of interest in the network was
IL8, a gene that showed a dramatic increase in expression of ~50-fold in 3D cells. Polymorphisms in this gene have been shown to be associated with a significantly higher risk of ovarian cancer [60, 61]. Studies also show that increases in IL8 is associated with increased tumor growth and metastases [62].

Various responses related to DNA integrity were altered, including the response to DNA damage, genetic instability, nucleotide excision repair, and the DNA damage checkpoint pathway. The hypoxic environment created within spheroids may lead to increased DNA damage. Spheroid culturing has shown to alter chromatin packaging which in turn improves DNA repair through what is known as the cell "contact" effect [63]. DNA damage via metabolic products and by-products, such as ROS, may decrease replication fidelity, resulting in increased mutagenesis. Mutations and chromosomal abnormalities can increase the risk of cancer through the activation of oncogenes or the inactivation of tumor suppressor genes. Complex DNA-damage response mechanisms have evolved in order to isolate and repair these mutations. One such mechanism is the nucleotide excision repair (NER) pathway. NER is able to eradicate a variety of DNA lesions due to its ability to circumvent recognition of the lesion itself and focus on a set of commonalities shared by many different lesions [40]. Our analysis showed a significant enrichment of the NER pathway when cells are cultured as 3D spheroids.

Sub-network enrichment analysis identifies that genes involved in epigenetic processes are enriched upon HEY cell growth as 3D spheroids

Epigenetic alterations can play a key role in promoting transformation and tumor growth [64–66], although the underlying mechanisms are still being worked out. We find two epigenetic
processes, DNA methylation and histone acetylation, to be enriched upon 3D growth. A number of genes are both up- and downregulated related to DNA methylation, and this process is affected by about 4–5% (Fig 6, for a complete list of all genes in the DNA methylation pathway see S4 Table). DNA methylation changes are seen in several cancer types and have been linked to changes in gene expression in highly metastatic tumors [67].

The process of histone acetylation is also significantly affected in both positive and negative fashions (Fig 7, for a complete list of all genes in the histone acetylation pathway see S4 Table). Histone acetylation has important roles in diverse processes including gene regulation, DNA damage repair, and DNA replication. Significant correlations between cancer patient survival and histone acetylation have been shown in several studies, although it has been associated with both better and worse prognoses depending on the specific cancer type [68, 69]. Thus, we conclude that growth as 3D spheroids may affect the epigenetic status of cancer cells, which could alter the tumorigenic properties of the cells.

Fig 7. Pathway for histone acetylation. A number of histone modifying enzymes were increased in expression in the 3D group, and this may be reflective of chromatin remodeling during cancer progression. Red indicates the gene or process is up-regulated and blue indicates the gene or process is down-regulated. All genes for histone acetylation pathways are listed in S4 Table.

https://doi.org/10.1371/journal.pone.0182930.g007
Conclusions
Spheroid formation more closely mimics that of an in vivo tumor due to the cells ability to form an extracellular matrix and cell adhesions. Here, using the HEY ovarian cancer cell line, we show that 3D growth affects a number of cellular processes, including the EMT process, multiple cellular stress pathways, DNA integrity pathways, and epigenetic pathways. As these pathways all could affect tumorigenesis and the response to chemotherapies, our studies suggest that using 3D culture instead of 2D monolayers may be more informative in studying the properties of ovarian cancer cell lines.

Supporting information
S1 Fig. Volcano plot analysis of HEY 2D vs. HEY 3D.
(TIF)
S1 Table. Primers for qPCR.
(DOC)
S2 Table. Complete list of transcripts affected by 3D culturing.
(XLSX)
S3 Table. Complete lists of geneset enrichment pathways and subnetwork enrichment analyses.
(XLSX)
S4 Table. Complete list of sub-networks that are related to the response to stress, the DNA methylation pathway and the histone acetylation pathway.
(XLSX)

Author Contributions
Conceptualization: TP CJM SDW.
Formal analysis: RH FC CJM.
Funding acquisition: SDW.
Investigation: TP CP CM RH CJM SDW.
Project administration: SDW.
Resources: SDW.
Supervision: SDW.
Validation: TP CJM SDW.
Visualization: TP CJM.
Writing – original draft: TP CJM SDW.
Writing – review & editing: TP CJM SDW.

References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Ca-Cancer J Clin. 2013; 63(1):11–30. https://doi.org/10.3322/caac.21166 PMID: 23335087
2. Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004; 351(24):2519–29. https://doi.org/10.1056/NEJMra041842 PMID: 15590954.

3. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007; 39(3):305–18. https://doi.org/10.1080/0033207071329914 PMID: 17558857.

4. Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. The Journal of cell biology. 1982; 95(1):333–9. PMID: 7142291; PubMed Central PMCID: PMC2112361.

5. Hay ED. An overview of epithelio-mesenchymal transformation. Acta anatomica. 1995; 154(1):8–20. PMID: 8714286.

6. Massagué J. TGFbeta in Cancer. Cell. 2008; 134(2):215–30. https://doi.org/10.1016/j.cell.2008.07.001 PMID: 18662538; PubMed Central PMCID: PMC3512574.

7. Zavadil J, Bottinger EP, TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24(37):5764–74. https://doi.org/10.1038/sj.onc.1208927 PMID: 16123809.

8. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer science. 2007; 98(10):1512–20. https://doi.org/10.1111/j.1349-7006.2007.00550.x PMID: 17645776.

9. Kunz-Schughart LA, Kreutz M, Knuechel R. Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol. 1998; 79(1):1–23. https://doi.org/10.1046/j.1365-2613.1998.00051.x PMID: 9614346.

10. Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Bio. 2007; 8(10):839–45. https://doi.org/10.1038/Nrm2236 PMID: 17684528.

11. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nature methods. 2007; 4(4):359–65. https://doi.org/10.1038/nmeth1015 PMID: 17396127.

12. Ghajar CM, Bissell MJ. Tumor Engineering: The Other Face of Tissue Engineering. Tissue Eng Pt A. 2010; 16(7):2153–6. https://doi.org/10.1089/tent.2010.0135 PMID: 20214448.

13. Santini MT, Rainaldi G, Indovina PL. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol. 2000; 36(2–3):75–87. PMID: 11033296.

14. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F, et al. beta 4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer cell. 2002; 2(3):205–16. https://doi.org/10.1016/S1535-6108(02)00125-3 PMID: 12242153.

15. Padron JM, Peters GJ. Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures. Investigational new drugs. 2006; 24(3):195–202. https://doi.org/10.1007/s10637-005-3691-5 PMID: 16193239.

16. Auersperg N, Ota T, Mitchell GWE. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. International Journal of Gynecological Cancer. 2002; 12(6):691–703. https://doi.org/10.1046/j.1525-1438.2002.01152.x PMID: 11445245.

17. Cvetkovic D. Early events in ovarian oncogenesis. Reproductive biology and endocrinology: RB&E. 2003; 1:68. https://doi.org/10.1186/1477-7827-1-68 PMID: 14577833; PubMed Central PMCID: PMC2398956.

18. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr., Ruff LE, et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. The American journal of pathology. 2001; 159(6):2071–80. PMID: 11733357; PubMed Central PMCID: PMC1850600.

19. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311–20. https://doi.org/10.1158/0008-5472.CAN-08-0365 PMID: 18519691.

20. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecologic oncology. 2012; 127(1):241–8. https://doi.org/10.1016/j.ygyno.2012.06.017 PMID: 22710073; PubMed Central PMCID: PMC3432677.

21. Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio—the analysis and navigation of molecular networks. Bioinformatics. 2003; 19(16):2155–7. PMID: 14594725.

22. Langlois VS, Martyniuk CJ. Genome wide analysis of Silurana (Xenopus) tropicalis development reveals dynamic expression using network enrichment analysis. Mechanisms of development. 2013; 130(4–5):304–22. https://doi.org/10.1016/j.mod.2012.12.002 PMID: 23295496.
23. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnology and bioengineering. 2003; 83(2):173–80. https://doi.org/10.1002/bit.10655 PMID: 12768623.

24. Penning TM. The aldo-keto reductases (AKRs): Overview. Chemico-biological interactions. 2015; 234:236–46. https://doi.org/10.1016/j.cbi.2014.09.024 PMID: 25304492; PubMed Central PMCID: PMC4388799.

25. Deng HB, Parekh HK, Chow KC, Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem. 2002; 277(17):15035–43. https://doi.org/10.1074/jbc.M112028200 PMID: 11842089.

26. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecologic oncology. 2009; 113(1):143–8. https://doi.org/10.1016/j.ygyno.2008.11.032 PMID: 19135710.

27. Wahlberg P, Nylander A, Ahlskog N, Liu K, Ny T. Expression and localization of the serine proteases high-temperature requirement factor A1, serine protease 23, and serine protease 35 in the mouse ovary. Endocrinology. 2008; 149(10):5070–7. https://doi.org/10.1210/en.2007-1736 PMID: 18566130.

28. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011; 3(12). https://doi.org/10.1101/cshperspect.a005058 PMID: 21917992; PubMed Central PMCID: PMC4388799.

29. Leone V, Ferraro A, Schepsis F, Federico A, Sepe R, Arca C, et al. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. Cancer Lett. 2015; 357(2):535–41. https://doi.org/10.1016/j.canlet.2014.12.010 PMID: 25497869.

30. Ferraro A, Schepsis F, Leone V, Federico A, Borbone E, Pallante P, et al. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. The Journal of clinical endocrinology and metabolism. 2013; 98(7):2834–43. https://doi.org/10.1210/jc.2012-2926 PMID: 23666966.

31. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun. 2004; 313(2):429–36. PMID: 14684180.

32. Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. Biochim Biophys Acta. 2014; 1846(2):638–54. https://doi.org/10.1016/j.bbcan.2014.10.007 PMID: 25450580; PubMed Central PMCID: PMC4261029.

33. Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.9651 PMID: 27248175.

34. Harjes U, Kalucka J, Carmeliet P. Targeting fatty acid metabolism in cancer and endothelial cells. Crit Rev Oncol Hematol. 2016; 97:15–21. https://doi.org/10.1016/j.critrevonc.2015.10.011 PMID: 26558689.

35. dos Santos CR, Domingues G, Matias I, Matos J, Fonseca I, de Almeida JM, et al. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids in health and disease. 2014; 13:16. https://doi.org/10.1186/1476-511X-13-16 PMID: 24428917; PubMed Central PMCID: PMC3896822.

36. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Archiv: an international journal of pathology. 2005; 446(5):475–82. https://doi.org/10.1007/s00428-005-1264-9 PMID: 15856292.

37. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(6):7335–42. https://doi.org/10.1007/s13277-014-2163-y PMID: 24880591.

38. Powell CD, Paullin TR, Aoisa C, Menzie CJ, Ubaldini A, Westerhede SD. The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model. PLoS One. 2016; 11(12):e0168389. https://doi.org/10.1371/journal.pone.0168389 PMID: 27997575; PubMed Central PMCID: PMC5172610.

39. Zimmermann R, Cerutti P. Active oxygen acts as a promoter of transformation in mouse embryo C3H/10T1/2/C18 fibroblasts. Proc Natl Acad Sci U S A. 1984; 81(7):2085–7. PMID: 6425826; PubMed Central PMCID: PMC345441.

40. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem. 1997; 272(32):19633–6. PMID: 9289489.

41. Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN oncology. 2012; 2012:137289. https://doi.org/10.5402/2012/137289 PMID: 23119185; PubMed Central PMCID: PMC3483701.

42. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009; 284(20):13291–5. https://doi.org/10.1074/jbc.R900010200 PMID: 19182219; PubMed Central PMCID: PMC2679427.
43. Wiemer EA. Stressed tumor cell, chemosensitized cancer. Nature medicine. 2011; 17(12):1552–4. https://doi.org/10.1038/nm.2593 PMID: 22146456.

44. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 2007; 130(6):1005–18. Epub 2007/09/25. https://doi.org/10.1016/j.cell.2007.07.020 PMID: 1789846; PubMed Central PMCID: PMC2586609.

45. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. The Journal of biological chemistry. 2005; 280(39):33097–100. https://doi.org/10.1074/jbc.R50010200 PMID: 16076838.

46. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761–72. https://doi.org/10.1038/nrc1716 PMID: 16175177.

47. Protti MP, Heltai S, Bellone M, Ferrarini M, Manfredi AA, Rugarli C. Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. Cancer Lett. 1994; 85(2):211–6. PMID: 7954339.

48. Maehara Y, Oki E, Abe T, Tokunaga E, Shibahara K, Kakeji Y, et al. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer. Oncology. 2000; 58(2):144–51.

49. Hatfield MP, Lovas S. Role of Hsp70 in cancer growth and survival. Protein and peptide letters. 2012; 19(6):616–24. PMID: 22519533.

50. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock proteins hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 1993; 85(7):570–4. PMID: 8455204.

51. Chant ID, Rose PE, Morris AG. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. British journal of haematology. 1995; 90(1):163–8. PMID: 7786780.

52. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer. 1992; 50(3):409–15. PMID: 1735610.

53. Nanbu K, Konishi I, Mandai M, Kuroda H, Hamid AA, Komatsu T, et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer detection and prevention. 1998; 22(6):549–55. PMID: 9824379.

54. Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. British journal of cancer. 2000; 82(1):85–7. https://doi.org/10.1054/bjoc.1999.0881 PMID: 10638971; PubMed Central PMCID: PMC2363193.

55. Pavan S, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, et al. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. Int J Cancer. 2014; 134(6):1289–99. https://doi.org/10.1002/ijc.28464 PMID: 23996744.

56. Gagou ME, Ganesh A, Phear G, Robinson D, Petermann E, Cox A, et al. Human PIF1 helicase supports DNA replication and cell growth under oncogenic-stress. Oncotarget. 2014; 5(22):11381–98. https://doi.org/10.18632/oncotarget.2501 PMID: 25394361.

57. Grassl ML, Palma CS, Thome CH, Lanfredi GP, Luqmani YA. Clinical and biological significance of HSP70 alpha in human breast cancer. Int J Cancer. 1992; 50(3):409–15. PMID: 1735610.

58. Wang K, Li D, Sun L. High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. Oncotargets and therapy. 2016; 9:377–86. https://doi.org/10.2147/OTT.99309 PMID: 28655586; PubMed Central PMCID: PMC4727521.

59. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005; 41(16):2449–61. https://doi.org/10.1016/j.ejca.2005.08.008 PMID: 16199154.

60. Koensgen D, Bruennert D, Ungureanu S, Sofroni D, Braicu EI, Sehouli J, et al. Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine. 2015; 71(2):334–8. https://doi.org/10.1016/j.cyto.2014.07.254 PMID: 25151459.

61. Wang Y, Xu RC, Zhang XL, Niu XL, Ou Y, Li LZ, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012; 59(1):145–55. https://doi.org/10.1016/j.cyto.2012.04.013 PMID: 22579115.

62. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010; 285(46):35462–70. https://doi.org/10.1074/jbc.M110.109579 PMID: 20826776; PubMed Central PMCID: PMC2975170.

63. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer metastasis reviews. 1994; 13(2):121–38. PMID: 7923546.
64. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours—lessons from the past. Nature reviews Clinical oncology. 2013; 10(5):256–66. https://doi.org/10.1038/nrclinonc.2013.42 PMID: 23546521; PubMed Central PMCID: PMC3730253.

65. Khan SA, Reddy D, Gupta S. Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? World journal of biological chemistry. 2015; 6(4):333–45. https://doi.org/10.4331/wjbc.v6.i4.333 PMID: 26629316; PubMed Central PMCID: PMC4657128.

66. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013; 153(1):38–55. https://doi.org/10.1016/j.cell.2013.03.008 PMID: 23540689; PubMed Central PMCID: PMC3648790.

67. Akhavan-Niaki H, Samadani AA. DNA methylation and cancer development: molecular mechanism. Cell biochemistry and biophysics. 2013; 67(2):501–13. https://doi.org/10.1007/s12013-013-9555-2 PMID: 23508887.

68. Chervona Y, Costa M. Histone modifications and cancer: biomarkers of prognosis? American journal of cancer research. 2012; 2(5):589–97. PMID: 22957310; PubMed Central PMCID: PMC3433108.

69. Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. British journal of cancer. 2007; 97(1):1–5. https://doi.org/10.1038/sj.bjc.6603844 PMID: 17592497; PubMed Central PMCID: PMC2359665.